ID
45819
Description
Principal Investigator: Daniel W. Cramer, MD, ScD, Brigham and Women's Hospital, Boston, MA, USA MeSH: Ovarian Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001034 The case-control data provided to dbGaP were collected under NCI grant number CA54419 which had 3 enrollment phases: I (1992-1997), II (1998-2002) and III (2003-2008). Altogether, CA54419 funded 15 years of data and specimen collection, resulting in one of the longest running population based case-control studies of ovarian cancer. The study goal was to examine reproductive factors, lifestyle exposures, and genetic background in relation to ovarian cancer risk. The project recruited cases from Eastern Massachusetts and New Hampshire, and became known as the New England-based Case-Control study (NECC) of ovarian cancer. 3957 ovarian cancer cases diagnosed at ages 18-80 and residing in Eastern Massachusetts and New Hampshire were identified through tumor boards and registries. Of these, 3083 (78%) were eligible and among those eligible, 2203 (71%) were enrolled. After excluding 127 non-epithelial and 35 mixed mesodermal tumors, 2041 cases with epithelial tumors of ovarian, primary peritoneal, and fallopian tube origin, including borderline malignancies were included. On average, cases were interviewed 10 months after their diagnosis. A pathologist reviewed pathology reports and recorded histologic subtype, grade, and stage. Mixed ovarian cancers described as predominantly one type were classified as that type. Undifferentiated, transitional cell tumors, or mixed serous/transitional cell tumors were counted as serous. Other mixed epithelial, malignant Brenner, and unspecified epithelial tumors were classified as other. 2100 controls were identified through random digit dialing (RDD), driver-license lists, and town-resident lists. During the first funding phase from 1992 to 1997, 420 (72%) controls identified through RDD and 102 (51%) through town-resident lists agreed to participate. From 1998 to 2008, only town-resident lists were used to identify potential controls. 4366 controls were identified, of whom 1426 (33%) were ineligible if they had died, moved, or were seriously ill or if they did not have a working telephone, speak English, or have at least one ovary. Of eligible controls, 1362 (46%) declined to participate by phone or via 'opt-out' postcard and 1578 (54%) were enrolled. Controls were frequency matched to cases by 5-year age groups and region of residence. In all phases, after written informed consent, demographic information, reproductive and medical history, and habits were assessed by in-person or telephone interview (in a few instances). All of the questions were framed with respect to a reference date defined as 1 year before the diagnosis date for women in the case group and the date of interview for those in the control group. This study was approved by institutional review boards at Dana Farber Harvard Cancer Center and Dartmouth Medical Center.
Link
Keywords
Versions (1)
- 6/29/23 6/29/23 - Simon Heim
Copyright Holder
Daniel W. Cramer, MD, ScD, Brigham and Women's Hospital, Boston, MA, USA
Uploaded on
June 29, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs001034 New England-Based Case-Control Study of Ovarian Cancer (NECC)
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for ovarian cancer.
- This subject phenotype table contains de-identified subject ID, study center and phase, reference age, year of birth, jewish ethnicity, race or ethnicity, body mass index, weight at reference age, height, menopausal status, smoking status, ever diagnosed with asthma, age when asthma was diagnosed, family history of ovarian cancer or premenopausal breast cancer, personal history of breast cancer, ever regularly used acetaminophen, aspirin or ibuprofen, ever used postmenopausal hormone therapy among postmenopausal subjects, ovulatory cycles, endometriosis or painful periods, parity, duration of breastfeeding, hysterectomy, age at hysterectomy, tubal ligation, age at tubal ligation, histologic type, alcohol consumption, birth control (n=4 variables; condoms, diaphragm or IUD ever used regularly or as primary method of birth control, and oral contraceptive use), husband or regular partner used body powder on his genital or rectal area, and powder applied to genital or rectal areas, non-genital or non-rectal areas, sanitary napkins or tampons, and underwear. The powder use counts times used per month, months used per year, age at first use, years used, first and second brand codes, texts, and contents.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for ovarian cancer.
- This subject phenotype table contains de-identified subject ID, study center and phase, reference age, year of birth, jewish ethnicity, race or ethnicity, body mass index, weight at reference age, height, menopausal status, smoking status, ever diagnosed with asthma, age when asthma was diagnosed, family history of ovarian cancer or premenopausal breast cancer, personal history of breast cancer, ever regularly used acetaminophen, aspirin or ibuprofen, ever used postmenopausal hormone therapy among postmenopausal subjects, ovulatory cycles, endometriosis or painful periods, parity, duration of breastfeeding, hysterectomy, age at hysterectomy, tubal ligation, age at tubal ligation, histologic type, alcohol consumption, birth control (n=4 variables; condoms, diaphragm or IUD ever used regularly or as primary method of birth control, and oral contraceptive use), husband or regular partner used body powder on his genital or rectal area, and powder applied to genital or rectal areas, non-genital or non-rectal areas, sanitary napkins or tampons, and underwear. The powder use counts times used per month, months used per year, age at first use, years used, first and second brand codes, texts, and contents.
C0680251 (UMLS CUI [1,2])
C1140680 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,3])
C0237096 (UMLS CUI [1,4])
C0024874 (UMLS CUI [1,5])
C0027969 (UMLS CUI [1,6])
C1706256 (UMLS CUI [2,1])
C1512714 (UMLS CUI [2,2])
C0011065 (UMLS CUI [2,3])
C0421434 (UMLS CUI [2,4])
C0421455 (UMLS CUI [2,5])
C1518422 (UMLS CUI [2,6])
C0205065 (UMLS CUI [2,7])
C0677930 (UMLS CUI [2,8])
C5680039 (UMLS CUI [3,1])
C1516879 (UMLS CUI [3,2])
C2828389 (UMLS CUI [3,3])
C4553182 (UMLS CUI [3,4])
C1548635 (UMLS CUI [1,2])
C0150103 (UMLS CUI [1,3])
C5453780 (UMLS CUI [1,4])
C0237096 (UMLS CUI [1,5])
C0009932 (UMLS CUI [2,1])
C1512714 (UMLS CUI [2,2])
C0011065 (UMLS CUI [2,3])
C0421434 (UMLS CUI [2,4])
C2051438 (UMLS CUI [2,5])
C1518422 (UMLS CUI [2,6])
C0039457 (UMLS CUI [2,7])
C0376245 (UMLS CUI [2,8])
C0029939 (UMLS CUI [2,9])
No comments